GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (FRA:MB8) » Definitions » Valuation Rank

Moberg Pharma AB (FRA:MB8) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Moberg Pharma AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Moberg Pharma AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (FRA:MB8) » Definitions » Valuation Rank
Comparable Companies
OSTO:ALZCUR OSTO:ERMA OSTO:VIVE XSAT:PMED XSAT:ODI XSAT:DICOT OSTO:NANEXA OSTO:NEWBRY OSTO:KLAR OSTO:RLS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
MBGPF:USA MOB:Sweden MOBs:UK MB8:Germany
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Website
https://www.mobergpharma.se
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.